Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 591-597, May 2011

Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients

  • Nishitha Reddy

      Affiliations

    • Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
    • ,
  • Katayoun Rezvani

      Affiliations

    • Department of Hematology, Hammersmith Hospitals Trust, Imperial College London, London, United Kingdom
    • ,
  • A. John Barrett

      Affiliations

    • Stem Cell Transplantation Section, Hematology Branch, NHLBI, National Institutes of Health, Bethesda, Maryland
    • ,
  • Bipin N. Savani

      Affiliations

    • Hematology and Stem Cell Transplantation Section, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
    • Corresponding Author InformationCorrespondence and reprint requests: Bipin N. Savani, MD, Hematology and Stem Cell Transplantation Section, Vanderbilt University Medical Center and VAMC, 3927 The Vanderbilt Clinic, Nashville TN 37232-5505.

Received 8 June 2010; accepted 12 August 2010. published online 23 August 2010.

Epstein-Barr virus (EBV)-associated postallogeneic stem cell transplantation (SCT) lymphoproliferative disorder (PTLD) is often life threatening. The risk of EBV reactivation is highest in older patients, T cell-depleted SCT (in vivo or vitro), and in unrelated or mismatched SCT. Cumulative numbers of patients with EBV reactivation and PTLD are rising as more patients at high risk for EBV reactivation and PTLD are receiving allo-SCT. Novel but easily applicable strategies are needed to prevent EBV reactivation and PTLD to serve the needs of the increasingly enlarging population of high-risk SCT recipients across the globe.

Key Words: EBV reactivation, PTLD, Stem cell transplantation, Rituximab, Sirolimus, Long-term survivors

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Financial disclosure: See Acknowledgments on page 595.

PII: S1083-8791(10)00346-0

doi:10.1016/j.bbmt.2010.08.007

Biology of Blood and Marrow Transplantation
Volume 17, Issue 5 , Pages 591-597, May 2011

Article Tools